

## **Impella vs intra-aortic balloon pump in patients with acute myocardial infarction complicated with cardiogenic shock: an updated systematic review and meta-analysis**


Muhammad Ahmed, Serish Bano, Mutahira Asif, F N U Sidra, Meva Ram, Shahida Bibi

*Department of Internal Medicine, Shaheed Mohtarma Benazir Bhutto Medical College Lyari, Karachi, Pakistan*


**Corresponding Author:** Muhammad Ahmed, Department of Internal Medicine, Shaheed Mohtarma Benazir Bhutto Medical College Lyari, Karachi, Pakistan. E-mail: [muhmmadahmed5515@gmail.com](mailto:muhmmadahmed5515@gmail.com)

**Key words:** Impella; intra-aortic balloon pump; cardiogenic shock; meta-analysis.

©The Author(s), 2025  
Licensee PAGEPress, Italy



**Figure S1.** Risk of bias for the included randomized-controlled-trials



**Figure S2.** PRISMA flowchart


**Table S1.** Search strategy used in each database

Search string	Database	Number of papers retrieved
(Impella OR percutaneous ventricular assist device OR Intra-aortic balloon pump OR IABP) AND (Acute Myocardial Infarction OR AMI OR acute MI OR AMICS OR STEMI OR NSTEMI) AND (Cardiogenic Shock OR Cardiac Shock)	PubMed	1,159
(Impella OR percutaneous ventricular assist device OR Intra-aortic balloon pump OR IABP) AND (Acute Myocardial Infarction OR AMI OR acute MI OR AMICS OR STEMI OR NSTEMI) AND (Cardiogenic Shock OR Cardiac Shock)	Cochrane Library	178
(Impella OR Intra-aortic balloon pump OR IABP) AND (Acute Myocardial Infarction OR AMI OR acute MI OR AMICS) AND (Cardiogenic Shock OR Cardiac Shock)	Google Scholar	13,300


**Table S2.** Newcastle-Ottawa quality assessment scale for cohort studies.

	Study Name					
	Alushi et al. 2019	Manzo-Silberman et al. 2013	Padberg et al. 2024	Pieri et al. 2018	Schrage et al. 2019	Kim et al. 2022
Selection (4)						
Representativeness of the exposed cohort	*	*	*	*	*	*
Selection of the non-exposed cohort	*	*	*	*	*	*
Ascertainment of exposure	*	*	*	*	*	*
Demonstration that outcome of interest was not present at start of the study	*	*	*	*	*	*
Comparability (2)						


Comparability of cohorts based on the design or analysis	**	**	*	**	**	**
Outcome (3)						
Assessment of outcome	*	*	*	*	*	*
Was follow-up long enough for outcomes to occur	*	*	*	*	*	
Adequacy of follow-up of cohorts	*	*	*	*	*	
Total (9)	9	9	8	9	9	7




**Figure S3.** Forest plot for long-term mortality




**Figure S4.** Forest plot for stroke




**Figure S5.** Forest plot for hemolysis




**Figure S6.** Forest plot for limb ischemia




**Figure S7.** Forest plot for major bleeding




**Figure S8.** Forest plot for transfusion




**Figure S9.** Forest plot for myocardial infarction




**Figure S10.** Forest plot for sepsis




**Figure S11.** Forest plot for acute kidney injury




**Figure S12.** Forest plot for the inotropic length of support




**Figure S13.** Forest plot for the mechanical ventilation




**Figure S14.** Scatter plot for mean age




**Figure S15.** Scatter plot for male sex %




**Figure S16.** Scatter plot for diabetes mellitus




**Figure S17.** Scatter plot for hypertension




**Figure S18.** Scatter plot for smoking




**Figure S19.** Scatter plot for dyslipidemia




**Figure S20.** Scatter plot for prior stroke




**Figure S21.** Scatter plot for prior MI




**Figure S22.** Scatter plot for PAD



**Figure S23.** Scatter plot for prior PCI



**Figure S24.** Scatter plot for prior CABG



**Figure S25.** Scatter plot for LVEF